Frequently expressed glypican‐3 as a promising novel therapeutic target for osteosarcomas
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Science"
DOI: 10.1111/cas.15521
Abstract: Osteosarcoma (OS) is the most common bone malignancy without a reliable therapeutic target. Glypican‐3 (GPC3) mutation and upregulation have been detected in multidrug resistant OS, and anti‐GPC3 immunotherapy can effectively suppress the growth of organoids.… read more here.
Keywords: therapeutic target; anti gpc3; cd133; expression ... See more keywords
Abstract 1785: Development of dual-payload anti-GPC3 antibody-drug conjugate by dual-payload antibody conjugation (AD2C) platform for hepatocellular carcinoma treatment
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-1785
Abstract: Glypican-3 (GPC3) has been reported as a promising target for the treatment of hepatocellular carcinoma (HCC). Although current therapies are available, tumor heterogeneity and the development of drug resistance continue to pose significant challenges to… read more here.
Keywords: treatment; anti gpc3; antibody; gpc3 ... See more keywords
A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r/r GPC3+ HCC).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.3049
Abstract: 3049Background: HCC was commonly diagnosed and identified as leading causes of cancer death in China. Using a 10% cutoff score, GPC3 was detected in 63.6% of HCCs. Safety and preliminary efficacy o... read more here.
Keywords: hcc; anti gpc3; gpc3 chimeric; study anti ... See more keywords